Societal CDMO, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-12-28: Form 8-K; Period of report 2018-12-20; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; Details 1.01.
- 2018-12-10: Form 8-K; Period of report 2018-12-10; Description 8.01 Other Events; Details 8.01.
- 2018-11-07: Form 8-K; Period of report 2018-11-07; Description 2.02 Results of Operations and Financial Condition; 8.01 Other Events; Details 2.02.
- 2018-10-09: Form 8-K; Period of report 2018-10-08; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2018-12-28 | 8-K | 2018-12-20 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders | 1.01 On December 20, 2018, Recro Pharma, Inc. (the “Company”) and its wholly-owned subsidiary Recro Gainesville LLC (“Recro Gainesville” and, together with the Company, “Recro”) entered into a Second Amendment to the Purchase and Sale Agreement dated March 7, 2015, among the Company, Recro Gainesville, Alkermes Pharma Ireland Limited (“APIL”), Daravita Limited and Alkermes US Holdings, Inc. (as successor to Eagle Holdings USA, Inc.), as amended (such agreement, the “Purchase and Sale Agreement,” and such amendment, the “Purchase and Sale Agreement Amendment”) and a Second Amendment to the Asset Transfer and License Agreement dated April 10, 2015, between Recro Gainesville and APIL, as amended (such agreement, the “License Agreement” and such amendment, the “License Agreement Amendment”). 3.02 The information in Item 1.01 above with regard to the Warrant Amendment is incorporated in this Item 3.02 by reference. 3.03 The information in Item 1.01 above with regard to the Warrant Amendment is incorporated in this Item 3.03 by reference. | d680324d8k.htm |
| 2018-12-10 | 8-K | 2018-12-10 | 8.01 Other Events | 8.01 On December 10, 2018, Recro Pharma, Inc. (the “Company”) issued a press release announcing the presentation of new data highlighting intravenous meloxicam’s effect on platelet function at the 72nd PostGraduate Assembly in Anesthesiology. | d671563d8k.htm |
| 2018-11-07 | 8-K | 2018-11-07 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On November 7, 2018, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2018. 8.01 On November 7, 2018, the Company updated information reflected in a slide presentation, including certain financial information, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. | d635548d8k.htm |
| 2018-10-09 | 8-K | 2018-10-08 | 8.01 Other Events | 8.01 On October 8, 2018, Recro Pharma, Inc. (the “Company”) issued a press release announcing that the United States Food and Drug Administration has set a Prescription Drug User Fee Act date of March 24, 2019 for its decision on the Company’s resubmitted New Drug Application for intravenous meloxicam for the management of moderate to severe pain. | d637202d8k.htm |
| 2018-10-01 | 8-K | 2018-10-01 | 8.01 Other Events | 8.01 On October 1, 2018, Recro Pharma, Inc. (the “Company”) issued a press release announcing the opening of an expanded 24,000 square foot GMP development and high potency product services facility in Gainesville, GA. | d630251d8k.htm |
| 2018-09-17 | 8-K | 2018-09-17 | 8.01 Other Events | 8.01 On September 17, 2018, Recro Pharma, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d586195d8k.htm |
| 2018-09-05 | 8-K | 2018-09-05 | 8.01 Other Events | 8.01 On September 5, 2018, Recro Pharma, Inc. (the “Company”) issued a press release announcing that it will present three poster presentations at PAINWeek 2018, taking place September 4-8, 2018, in Las Vegas, NV. | d603527d8k.htm |
| 2018-09-04 | 8-K | 2018-09-04 | 8.01 Other Events | 8.01 On September 4, 2018, Recro Pharma, Inc. (the “Company”) issued a press release providing a regulatory update following receipt of the official meeting minutes from a July 2018 Type A meeting with the U.S. Food and Drug Administration relating to a path forward for intravenous meloxicam, the Company’s lead product candidate for the management of moderate to severe pain. | d597781d8k.htm |
| 2018-08-07 | 8-K | 2018-08-07 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On August 7, 2018, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2018. 8.01 On August 7, 2018, the Company posted certain financial information on its website relating to the reconciliation of certain non-GAAP financial measures for the second quarter ended June 30, 2018 to the comparable measures calculated and presented in accordance with U.S. GAAP. | d583407d8k.htm |
| 2018-05-24 | 8-K | 2018-05-24 | 8.01 Other Events | 8.01 On May 24, 2018, Recro Pharma, Inc. issued a press release announcing the receipt of a Complete Response Letter from the U.S. Food and Drug Administration Office of Drug Evaluation II regarding the New Drug Application for IV meloxicam. | d709891d8k.htm |
| 2018-05-10 | 8-K | 2018-05-10 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 The information in Item 8.01 below regarding certain financial slides in the updated slide presentation of Recro Pharma, Inc. (the “Company”) and slides 3, 33, 35 and 36 of the presentation attached hereto as Exhibit 99.1, are incorporated into this Item 2.02 by reference. 8.01 On May 10, 2018, the Company updated information reflected in a slide presentation, including certain financial information, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d585828d8k.htm |
| 2018-05-09 | 8-K | 2018-05-09 | 2.02 Results of Operations and Financial Condition | 2.02 On May 9, 2018, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2018. | d587906d8k.htm |
| 2018-05-07 | 8-K | 2018-05-07 | 8.01 Other Events | 8.01 On May 7, 2018, Recro Pharma, Inc. announced the receipt of issue notifications for three patents covering intravenous meloxicam from the U.S. Patent and Trademark Office. | d584406d8k.htm |
| 2018-04-30 | 8-K | 2018-04-30 | 8.01 Other Events | 8.01 On April 30, 2018, Recro Pharma, Inc. announced that it presented a poster presentation entitled “In Monkeys, Reversal of the Ultra-Short Acting NMBA 1759-50 by Either D- or L-cysteine is Equally Rapid. | d579335d8k.htm |
| 2018-03-09 | 8-K | 2018-03-09 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 The information in Item 8.01 below regarding certain financial slides in the updated slide presentation of Recro Pharma, Inc. (the “Company”) and slides 3, 33, 35 and 36 of the presentation attached hereto as Exhibit 99.1, are incorporated into this Item 2.02 by reference. 8.01 On March 9, 2018, the Company updated information reflected in a slide presentation, including certain financial information, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d463589d8k.htm |
| 2018-02-28 | 8-K | 2018-02-28 | 7.01 Regulation FD Disclosure | 7.01 As previously announced, Recro Pharma, Inc. (the “Company”) will host an Analyst and Investor Day on Wednesday, February 28, 2018 from 9:30 am to 12:00 pm ET in New York City. | d544101d8k.htm |
| 2018-02-27 | 8-K | 2018-02-27 | 2.02 Results of Operations and Financial Condition | 2.02 On February 27, 2018, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2017. | d544751d8k.htm |
| 2018-02-07 | 8-K | 2018-02-07 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 Recro Pharma, Inc. (the “Company”) is currently in the process of finalizing its financial results for the fiscal year ended December 31, 2017. 8.01 On February 7, 2018, the Company updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d442079d8k.htm |
| 2018-01-08 | 8-K | 2018-01-08 | 8.01 Other Events | 8.01 On January 8, 2018, Recro Pharma, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d522467d8k.htm |
| 2018-01-08 | 8-K | 2018-01-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 3, 2018, Recro Pharma, Inc. (the “Company”) announced that Michael Celano has been promoted to Chief Operating Officer and Ryan D. Lake has been promoted to Chief Financial Officer. | d522134d8k.htm |